Roghmann Florian, Goebell Peter J, Dyrskjøt Lars, van Rhijn Bas W G, Käfferlein Heiko U, Hakenberg Oliver, Stenzl Arnulf, Burger Maximilian, Pesch Beate, Benderska-Söder Natalya, Schmitz-Dräger Bernd J
Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany.
Department of Urology and Pediatric Urology, Friedrich-Alexander University, Erlangen, Germany.
Bladder Cancer. 2022 Mar 11;8(1):1-4. doi: 10.3233/BLC-211602. eCollection 2022.
Marker research, and in particular urine bladder cancer marker research throughout the past three decades, devours enormous scientific resources in terms of manpower (not to mention time spent on reviewing and editorial efforts) and financial resources, finally generating large numbers of manuscripts without affecting clinical decision making. This is mirrored by the fact that current guidelines do not recommend marker use due to missing level 1 evidence. Although we recognize the problems and obstacles, the authors of this commentary feel that the time has come to abandon the current procedures and move on to prospective trial designs implementing marker results into clinical decision making. Our thoughts and concerns are summarized in this comment.
在过去三十年中,标志物研究,尤其是膀胱癌标志物研究,耗费了大量的人力科学资源(更不用说用于审阅和编辑工作的时间)和财力资源,最终产生了大量的手稿,却并未影响临床决策。目前的指南因缺乏一级证据而不推荐使用标志物,这一事实反映了上述情况。尽管我们认识到其中的问题和障碍,但本评论的作者认为,现在是时候摒弃当前的程序,转向将标志物结果纳入临床决策的前瞻性试验设计了。我们的想法和担忧总结于此评论中。